Results 1 to 10 of about 165,965 (304)

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

Molecular Metabolism, 2021
Objective: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide.
Timo Müller, Davide Calebiro, Martin Klingenspor   +2 more
exaly   +3 more sources

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Frontiers in Endocrinology, 2021
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of ...
Minmin Han, , Lijuan Cui
exaly   +2 more sources

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

Circulation, 2022
Patients with type 2 diabetes are at high risk for development of cardiovascular disease, including myocardial infarction, stroke, heart failure, and cardiovascular death.
Nikolaus Marx, Naveed Sattar, Mansoor Husain   +2 more
exaly   +2 more sources

Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study

International Immunopharmacology
BACKGROUND GLP-1 receptor agonists, traditionally used for treating type 2 diabetes mellitus and obesity, have demonstrated anti-inflammatory properties.
Mohammad Hosny Hussein, Eman A Toraih, Rami Elshazli   +2 more
exaly   +2 more sources

An Update on GLP‐1 Receptor Agonists [PDF]

Journal of Diabetes
Zachary Bloomgarden
doaj   +2 more sources

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists [PDF]

Endocrinology and Metabolism, 2021
Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established
Hun Jee Choe, Young Min Cho
doaj   +1 more source

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions [PDF]

Kidney Research and Clinical Practice, 2022
With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management.
Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo   +4 more
doaj   +1 more source

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.

The Lancet Diabetes and Endocrinology, 2021
BACKGROUND GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain.
N. Sattar, Matthew M. Y. Lee, S. Kristensen, K. Branch, S. Del Prato, N. Khurmi, C. Lam, R. Lopes, J. McMurray, R. Pratley, J. Rosenstock, H. Gerstein   +11 more
semanticscholar   +1 more source

The benefits of GLP1 receptors in cardiovascular diseases

Frontiers in Clinical Diabetes and Healthcare, 2023
Glucagon like peptide-1 (GLP-1) receptor agonists are well established drugs for the treatment of type 2 diabetes (T2D). In addition to glycemic control, GLP-1 receptor agonists have beneficial other effects. They act by binding to GLP-1 receptors, which
Lamija Ferhatbegović, Denis Mršić, Amra Macić-Džanković   +2 more
doaj   +1 more source

Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy

American Heart Journal Plus, 2022
Select glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated cardiovascular benefits in both primary and secondary prevention populations and are recommended in multiple guidelines for cardiovascular risk reduction in people with type 2 ...
Elizabeth Van Dril, Margaret Allison, Christie Schumacher   +2 more
doaj   +1 more source